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Abstract
Background: Zoonotic sleeping sickness, or HAT (Human African Trypanosomiasis), caused by infection with
Trypanosoma brucei rhodesiense, is an under-reported and neglected tropical disease. Previous assessments of the
disease burden expressed as Disability-Adjusted Life Years (DALYs) for this infection have not distinguished T.b.
rhodesiense  from infection with the related, but clinically distinct Trypanosoma brucei gambiense form.  T.b.
rhodesiense occurs focally, and it is important to assess the burden at the scale at which resource-allocation
decisions are made.
Methods: The burden of T.b. rhodesiense was estimated during an outbreak of HAT in Serere, Uganda. We
identified the unique characteristics affecting the burden of rhodesiense HAT such as age, severity, level of under-
reporting and duration of hospitalisation, and use field data and empirical estimates of these to model the burden
imposed by this and other important diseases in this study population. While we modelled DALYs using standard
methods, we also modelled uncertainty of our parameter estimates through a simulation approach. We
distinguish between early and late stage HAT morbidity, and used disability weightings appropriate for the T.b.
rhodesiense form of HAT. We also use a model of under-reporting of HAT to estimate the contribution of un-
reported mortality to the overall disease burden in this community, and estimate the cost-effectiveness of
hospital-based HAT control.
Results: Under-reporting accounts for 93% of the DALY estimate of rhodesiense HAT. The ratio of reported
malaria cases to reported HAT cases in the same health unit was 133:1, however, the ratio of DALYs was 3:1.
The age productive function curve had a close correspondence with the HAT case distribution, and HAT cases
occupied more patient admission time in Serere during 1999 than all other infectious diseases other than malaria.
The DALY estimate for HAT in Serere shows that the burden is much greater than might be expected from its
relative incidence. Hospital based control in this setting appears to be highly cost-effective, highlighting the value
of increasing coverage of therapy and reducing under-reporting.
Conclusion: We show the utility of calculating DALYs for neglected diseases at the local decision making level,
and emphasise the importance of improved reporting systems for acquiring a better understanding of the burden
of neglected zoonotic diseases.
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Background
Human African trypanosomosis (HAT), also known as
sleeping sickness, is caused by Trypanosoma brucei gambi-
ense or T. b. rhodesiense, the former occurring in West and
Central Africa and the latter restricted to East Africa, with
a predominant focus in eastern Uganda. HAT is a fatal dis-
ease if not treated [1], and during the clinical disease,
patients suffer a variety of debilitating symptoms and
sequelae. A commonly used index for expressing the bur-
den of disease is disability adjusted life years (DALYs), a
generic health measure incorporating both mortality and
morbidity and used to gauge the relative public health
importance of different diseases [2,3]. WHO/World Bank
burden of disease studies [4] estimate the total DALY for
HAT to be 1.53 million. For Africa, this compares to 40.9
million for malaria, 9.27 million for tuberculosis, 1.33
million for schistosomiasis and 2.01 million for lym-
phatic filariasis. Amongst the human infectious and para-
sitic diseases in Africa, human trypanosomiasis is ranked
ninth and thirteenth out of 25 for mortality and DALYs,
respectively, while among vector-borne diseases, HAT
ranks second and fourth, respectively. Given that HAT
tends to occur where there is a breakdown in control and
that it affects mainly rural poor people, it is under-
reported compared to other diseases [5,6]; this situation is
mirrored with other neglected diseases [7,8]. Unlike
malaria, HAT is always fatal if not treated and the costs of
treatment, usually requiring hospitalisation, are high [9].
Because of this, it is particularly important to assess the
cost burden to the health services in addition to the aggre-
gate health burden to individual patients [10,11].
T. b rhodesiense HAT is an acute zoonotic disease and the
available evidence supports the hypothesis that cattle are
an important reservoir [12-14]. While often considered
together, rhodesiense and gambiense HAT are different
diseases both clinically and epidemiologically [15];
because rhodesiense HAT is less prevalent and less widely
distributed than gambiense HAT, current published esti-
mates of HAT morbidity are based on parameters of the
latter [16,17] – eg using a disability weighting of 0.35 for
each non-fatal case [18]. However, in its major focus of
eastern Uganda, it has been responsible for many deaths
throughout the 20th  century [19], and because of its
regional importance in eastern Africa, focal pattern of
occurrence, rapid progression, and zoonotic nature [20],
it is important to specifically estimate the burden of
rhodesiense HAT in communities. Importantly, trypano-
somiasis control in this area could have both public
health and veterinary benefits.
This paper examines how the unique features of rhode-
siense HAT influence its burden on the local population
and health services in Serere, part of Soroti District, east-
ern Uganda. This is the focal point for patients reporting
during an ongoing epidemic of rhodesiense HAT [21]. In
addition, these estimates are compared to local burden of
disease estimates for malaria and other conditions in the
same health unit over the same time period. These esti-
mates are important for understanding the burden of
rhodesiense HAT generally, and for assisting the decision-
making process at sub-national or district levels in
affected countries – an increasingly important objective
[22-27]. Recently, DALYs have been calculated at the vil-
lage level for T.b. gambiense in the Democratic Republic of
Congo [17].
Methods
Health burden indices
We estimate two health burden indices for a rhodesiense
HAT outbreak in Serere health sub-district, in north-east-
ern Uganda; firstly the DALY, and secondly an estimate of
the costs to the health sub-district based on the total costs
of hospitalization and treatment for the disease. Both
measures of burden were estimated for one calendar year,
using the variability in the data from 1999–2005 to cap-
ture the uncertainty in our estimates.
Disability Adjusted Life Years (DALYs)
DALY calculations followed the general methods used in
the first Global Burden of Disease study [2,16], and sub-
sequent World Health Report estimates [4], employed a
discount rate of 3% [2] and were conducted with and
without age-weighting [28]. The features of rhodesiense
HAT that need to be considered in DALY estimation are
the age and sex profile of patients, the severity of illness,
the case fatality rate and the duration of morbidity. The
information required to calculate the DALY is summa-
rized in Table 1. Our calculations follow a stochastic
framework; the age-specific YLL, YLD and DALY are esti-
mated using a stochastic model that captures both uncer-
tainty (from estimates) and annual variability in the input
data (data inputs are drawn from the years 1999–2005),
and reflects this uncertainty and variability in the model
outputs. We run 10,000 Monte-Carlo simulations of the
model employing Latin Hypercube sampling [29], using
the @Risk software package (Palisade, Newfield, NY,
USA; version 4.05); our model is constructed to consist-
ently sample values for input variables from the data from
the same year at each iteration. We report outputs with
their 95% confidence intervals.
Years of life lost (YLL)
The number of HAT deaths in Serere health sub-district,
was estimated as a function of both the number of
reported deaths and the rate of case under-reporting. Our
estimate of the rate of under-reporting is based on a previ-
ously published methodology [30] in which the early:late
stage ratio is a crucial parameter. Two under-reporting
rates, 0% and 69% were applied, representing completeBMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
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reporting for the former and a previous estimate for this
population [21] for the latter. This under-reporting rate
was applied to model the number of unreported cases
each year, by multiplying the rate by the total number of
male and female cases presenting in each age group from
1999–2005. Thus, for every ten cases presenting at the
health facility, an additional seven (95% CI 4–10.2) were
estimated to be unreported in the community. All unre-
ported cases are assumed to remain undetected, receiving
no treatment and resulting in death. To reflect the uncer-
tainty in the rate of under-reporting, the value of this
parameter was, at each iteration of the model, drawn from
a gamma distribution with parameters α = 20.063 and β =
0.034. The life expectancy at the age of death was based on
a Uganda-specific life-table with a life expectancy at birth
of 45 years [31]. Using national (rather than the a model
– eg United Nations West 26) life table for regional com-
parisons is consistent with established methodologies
[16,32,33]. The distribution of age of death was estimated
from the distribution of ages of all cases of HAT admitted
to Serere health centre during 1999–2005, though all
inputs to the calculations were drawn, on each iteration of
the model, from the same calendar year. We assumed that
the case fatality rate is constant across age; while there are
no T.b. rhodesiense-specific studies on this, recent work on
T.b. gambiense has shown this to be a reasonable assump-
tion [34].
Years of life lived with Disability (YLD)
The disability weighting used for HAT up to the present is
0.35 [16,35] based on clinical cases of T. b. gambiense. T.b.
rhodesiense HAT is a more acute disease, with a greater
degree of incapacity suffered throughout the period of
infection than T.b. gambiense; untreated cases die within
3–9 months of infection, vs. up to 2–3 years for T.b. gam-
biense [9,19]. Additionally, HAT occurs in two stages: stage
1 occurs while the parasite is present in the blood and
lymphatic system, and stage 2 when the parasite has
crossed the blood-barrier and infects the central nervous
system. The previously used disability weighting for HAT
[16] does not account for the sequelae associated with the
different stages. Here, we apply different disability weights
for early and late stage disease, and use weights appropri-
ate for rhodesiense HAT. Murray and Lopez [2] describe a
range of disability weight classifications that are deter-
mined by the severity of disability – based on the clinical
expert opinion of one of the authors (MO) over 15 years
of T.b. rhodesiense HAT treatment, we have used a disabil-
ity weighting of 0.21 (equivalent to that for malaria) for
early stage T.b. rhodesiense HAT and 0.81 for late stage T.b.
rhodesiense HAT (though we also present a final output
using 0.35 for late stage HAT for comparative purposes, to
represent uncertainty about the disability weight [36]). A
weight of 0.81 equates to the inability to undertake basic
activities associated with daily living without assistance.
In our analysis, early stage disability was applied to both
early and late stage patients (assuming that patients pre-
senting in the late stage had previously suffered early stage
symptoms), and late stage disability was applied to late
stage patients alone, in each case for the estimated dura-
tion of the symptoms associated with each stage. Duration
of illness pre-admission in each stage were taken from
Odiit et al. [37]; median time of illness pre-admission for
early and late stage were 21 days and 61 days, respectively.
The median duration of hospital stay for non-fatal cases in
either the late or early stage (38 days) was obtained from
the HAT case records at Serere Health Centre for 1999 (the
data quality for this parameter for other years was not suf-
ficient to include them). We used a non-parametric boot-
strap to model the uncertainty in the duration of early and
late stage illness, as well as the duration of hospital stay.
Briefly, the non-parametric bootstrap estimates the uncer-
tainty in a parameter by re-sampling from the distribution
of the sample itself. The advantage of this method is that
it allows us to model uncertainty in the time variables of
the model without making any distributional assump-
tions about the data. The duration of illness estimate did
not account for post-treatment disability; physical and
mental retardation in children caused by HAT has been
reported [38], as have other longer term sequelae, but they
Table 1: Information required for the estimation of disability-adjusted life years (DALYs) for rhodesiense sleeping sickness
Information type Specific data required Data sources
Years-of-life-lost (YLL) 1) Number of deaths - health unit records of case fatality by age/sex
- case under-reporting estimates (by age and sex, based on Odiit et al. 
[30] and Fèvre et al. [21])
2) Life expectancy - Uganda-specific life table for 2000 [31]
3) Distribution of age at death - health unit records of case age (with or without age-weighted case 
fatality rate and under-reporting rate)
Years-of-life-lived with disability (YLD) 1) Disability weighting - expert opinion – see text (rhodesiense disability weighting not 
previously explicitly provided [16, 35])
2) Duration of illness - pre-admission from Odiit et al. [37]
- post-admission from health unit records of cases
3) Age-weighting of productivity - health unit records of case ageBMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
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are not considered here. Our estimates should therefore
be considered conservative.
Costs to the local health system
The costs to the health system per HAT patient were esti-
mated as the product of the total annual hospital stay in
days and a standard daily cost. Total hospital stay was
determined by multiplying the mean stay per patient
(using a non-parametric bootstrap, as above, based on all
patients diagnosed parasitologically in Serere during
1999) by the total number of patients in any given year
(1999–2005), over 10,000 model iterations. A standard
cost range per hospital day in 1999/2000 was estimated in
consultation with staff at the Serere health centre and
applied to all years. They considered that daily hospital
costs were similar for all diseases for which patients were
admitted as inpatients to their health centre and estimated
it at between 3000–4000 Uganda Shillings (US$ 1.75 to
US$ 2.35 per patient, with a most likely value of US$ 2 per
patient). We used a betapert distribution to model this
parameter. The drug costs for a full course of HAT treat-
ment are estimated to be US$ 35 and US$ 63 for early and
late stage patients respectively (WHO, 1998); these were
modelled as point estimates. This does not include patient
costs such as travel to hospital, which have been examined
elsewhere for both T.b. rhodesiense [39] and T.b. gambiense
[17]. Using these data we have also modelled the cost-
effectiveness of the hospital-based intervention at pre-
venting a loss of DALYs due to HAT, expressed as US$/
DALYs averted.
Relative burden of HAT compared to other diseases
The most commonly diagnosed illness in the study area
was malaria. The DALY for malaria was estimated using
data from all diagnosed (either clinically or parasitologi-
cally) inpatient and outpatient malaria cases and recorded
deaths at the Serere health centre during 1999; non-HAT
data were only available for 1999. For the YLL calculation,
each reported death due to malaria in 1999 and its age at
death were obtained. For the YLD calculation, a disability
weighting of 0.21 per episode of all types of malaria was
used [16] for all age groups; duration of morbidity for
malaria was 0.01 years for an outpatient case irrespective
of age, and 0.03 and 0.07 years for inpatients <5 and ≥ 5
years old, respectively [16].
We also compared the relative impact of HAT, malaria and
tuberculosis in different age groups. This was done by cal-
culating the age distribution of HAT, malaria and tubercu-
losis cases recorded at the Serere health centre and
comparing it qualitatively to the age-productivity function
curve [2].
A final comparison assessed the relative hospital costs of
HAT to all other diseases for which patients were admitted
at the Serere health centre. For each disease, total hospital
stay (for 1999 non-HAT diseases) was calculated and mul-
tiplied by the standard cost per hospital day as described
above. Tuberculosis was excluded because of the current
strategy of direct observed therapy (DOTS) in lieu of hos-
pital admission. HIV/AIDS was also excluded because of
its association with concurrent opportunistic infections.
Results
The data at Serere health centre included 72 cases (4
reported deaths) of HAT in 1999, 51 cases (3 reported
deaths) in 2000, 45 cases (2 reported deaths) in 2001, 87
cases (1 reported death) in 2002, 121 cases (8 reported
deaths) in 2003, 99 cases (5 reported deaths) in 2004 and
93 cases (4 reported deaths) in 2005. The 1999 records
included 11,228 diagnosed malaria cases (including 763
cases of inpatient severe malaria), with 104 cases in the
tuberculosis register.
Disability Adjusted Life Year (DALY) estimates for 
Rhodesiense HAT
The modelled annual age-specific number of reported
cases, reported deaths, estimated unreported cases/deaths
(assuming a 0 or 69% under-reporting rate), and non-age-
weighted discounted YLL (DYLL) are listed in Table 2. If
we consider that all cases were reported (0% under-report-
ing) then the non-age weighted total YLL would be only
65. Of greater importance was under-reporting; only 4
(95%CI = 1 – 8; median = 4) deaths were recorded at the
health centre while we estimate that an additional 59
(95% CI = 25 – 109; median = 57) deaths due to HAT
went unreported [30]. The age-specific, non-age-
weighted, total YLLs for a 69% under-reporting rate are
also listed, summing to a total of 1136 (95% CI = 493 –
2132; median = 1080). If age-weighting is applied, the
total YLL estimate is 1405 (95% CI = 609 – 2657; median
= 1333).
The years of life lived with disability (YLD), for cases that
recovered due to treatment are listed in Table 3. The non-
weighted total YLD is 20.5 (95% CI = 9.2 – 30.0; median
= 21.9). If age-weighting is applied the total YLD estimate
increases marginally to 24.7 (95% CI = 11.4 – 37.1;
median = 25.7).
The total estimated DALYs for rhodesiense HAT are shown
in Table 4. Based on 69% under-reporting and no age-
weighting, the mean annual DALY burden in Serere was
1157 (95% CI = 504 – 2159; median = 1103) compared
to 86 (95% CI = 35 – 162; median = 82) based on 0%
under reporting (Table 4); the majority (93%) of this
DALY burden was due to mortality in unreported cases.
When applying a disability weight per late stage HAT epi-
sode of 0.35 [18], the estimated DALY burden for this
population is 1148 (95% CI = 499 – 2146; median =B
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Table 2: Years of Life Lost (YLL) due to rhodesiense sleeping sickness in Serere, Uganda. Values are mean values (with lower and upper 95% confidence intervals) from 10,000 Monte-Carlo 
simulations, derived from data from 1999–2005.
Age of onset Study 
population
Annual reported non-
fatal early cases
Annual reported 
non-fatal late cases
Annual 
reported 
deaths
Annual YLLs with 
0% under-
reporting (age 
weighted)
Annual YLLs with 
0% under-
reporting (non-age 
weighted)
Annual deaths with 
69% under-
reporting
Annual YLLs with 
69% under-
reporting (age 
weighted)
Annual YLLs with 
69% under-
reporting (non-age 
weighted)
0–4 7145 1.6 (0–3) 2.1 (0–4) 0.1 (0–1) 4 (0–28) 3.5 (0–24.8) 2.8 (0.5–5.5) 86.9 (17–170) 71.4 (13.9–140.1)
5–14 12432 5.7 (2–13) 11.4 (3–17) 1 (0–3) 33.2 (0–100.5) 24 (0–73.3) 12.7 (4.2–27) 423.2 (141.1–
902.5)
308.7 (102.4–
660.5)
15–29 12687 9.9 (3–16) 16.7 (9–23) 0.7 (0–2) 19.7 (0–52.8) 14.9 (0–40.4) 19 (7–34.8) 552.7 (199.1–
1027.2)
406.3 (147.3–
752.8)
30–44 6857 4.6 (1–8) 9.4 (4–18) 0.6 (0–1) 10.3 (0–18.7) 9.8 (0–18) 10.1 (4.4–21.8) 210.6 (90.6–444.7) 184.6 (79.8–391.8)
45–59 4668 2.4 (0–5) 6.7 (3–10) 0.1 (0–1) 1.9 (0–13.1) 2.1 (0–15) 6.5 (2.1–12.2) 83.4 (28.6–154.3) 93.3 (31.4–171.5)
60–69 1850 2.4 (0–5) 4.1 (3–7) 0.9 (0–2) 6.1 (0–16.4) 8.7 (0–22.6) 5.4 (1.6–10.4) 39.4 (10.4–74.3) 55.6 (15–105.9)
70–79 781 0.1 (0–1) 2.3 (0–4) 0.3 (0–1) 1.1 (0–4.4) 1.9 (0–7.5) 1.9 (0–4.6) 8 (0–19.2) 13.5 (0–32.5)
80+ 235 0.6 (0–3) 0.4 (0–2) 0.1 (0–1) 0.2 (0–1.2) 0.4 (0–3) 0.8 (0–3.5) 1.6 (0–6.5) 3.5 (0–14.3)
Totals 46655 27.3 (7–48) 53.3 (24–73) 3.9 (1–8) 76.4 (17.3–160) 65.4 (16.2–
132.1)
59.2 (25.2–
109.1)
1405.8 (608.8–
2657.2)
1136.8 (493–
2132.2)BMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
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1092), reflecting again the emphasis on mortality as the
main driver in overall burden in this study.
Costs to the local health system of rhodesiense HAT
Between 1999 and 2005, the mean number of recorded
HAT patients per year in Serere was 84.5 (95% CI = 47 –
129; median = 88); with a mean hospital stay per patient
of 47 (95% CI = 37 – 58; median = 46) days. The standard
daily health cost estimated by staff at the Serere health
centre was US$ 1.75–2.35. The mean total annual cost of
HAT to the Serere health system was US$ 7649 (95% CI =
3668 – 12,773; median = 7744). Drug costs are not met
by the district and national health services as drugs are
donated by the World Health Organization following
agreements with the manufacturers [40]. The mean
annual costs of these drugs for late stage cases (melarso-
prol) was US$ 3357 (95% CI = 1512 – 4599; median =
3780) and that for early stage cases (suramin) US$ 955
(95% CI = 245 – 1680; median = 1085), giving a total of
an additional US$ 4312 (95% CI = 2247 – 6279; median
= 4445) for drugs per year; therefore, the total costs
(drugs+hospital costs) of treating HAT in Serere was US$
11,961 (95% CI = 5950 – 19,025; median = 12,362), or
US$ 147 (95% CI = 125 – 173; median = 147) per patient.
We modelled the DALYs averted as a result of the hospital
intervention by comparing annual mortality i) with the
hospital treatment (mean of 4 annual deaths as modelled
above) and ii) under the alternate assumption that all
cases presenting at the hospital die, as would be the case
in the absence of treatment. This part of the analysis did
not account for under-reporting in the community, and
we used non age-weighted outputs. If each patient pre-
senting to hospital died, this would represent 1570 (95%
CI = 876 – 2401; median = 1710) DALYs lost, while we
have already shown that 86 (95% CI = 35 – 162) DALYs
were lost with the observed intervention. The hospital-
based intervention, as observed, therefore saved 1484
(95% CI = 841 – 2239; median = 1488) DALYs, at a cost
to the health authorities of US$ 11,961 (95% CI = 5950 –
19,025), including drug costs – see above. This equates to
US$ 8.06 (95% CI = US$ 7.1 – 8.5; median = 8.31) per
DALY averted for the reported, hospitalised cases.
Comparison to local burdens of other diseases
The most common disease at the Serere health centre was
malaria. A total of 11,228 cases were diagnosed in 1999
(see Table 5), mainly by using clinical signs, with only a
few cases being confirmed parasitologically. All recorded
HAT cases were parasitologically confirmed. The relative
burden of malaria and HAT differs greatly depending on
whether DALY estimates or total case numbers are com-
pared (see Table 5). This is because of the relatively lower
reported case-fatality rate for malaria (2 out of 11,228
compared to a mean of 4 out of a mean of 80 reported
cases for HAT) and the shorter duration of illness for a
malaria patient (average of 4 days), with most being
treated as outpatients; all diagnosed HAT cases were hos-
pitalised as inpatients. DALYs, particularly the YLL com-
ponent, depend on an accurate estimation of reported
deaths. If we assume no under- or over- reporting of
malaria [41], the mean DALY estimate for malaria in
Serere is 271 and that for HAT 86 (Table 5). 82% (251) of
the DALY burden for malaria was accounted for by chil-
dren less than 5 years, a finding consistent with other
studies [42,43].
The age distribution of HAT, malaria and tuberculosis
cases at the Serere health centre differed. Figure 1 shows
the age distribution for 763 severe malaria cases admitted
to the Serere health centre in 1999, 104 tuberculosis cases
treated in 1999 and 115 HAT cases admitted to the Serere
health centre between January 1999 and August 2000. The
age pattern of HAT cases has a peak in the 20–29 age cat-
Table 3: Years of Life Lived with Disability (YLD) due to rhodesiense sleeping sickness in Serere, Uganda. Disability weights of 0.21 and 
0.81 were used for early and late stage cases, respectively. Values are mean values (with 95% confidence intervals) from 10,000 Monte-
Carlo simulations, derived from data from 1999–2005.
Age of onset (years) Number of recovered patients 
(early+late)
Total non-age weighted YLD (early+late) Total age weighted YLD (early+late)
0–4 3.7 (1–6) 0.9 (0–1.5) 0.3 (0–0.6)
5–14 17.1 (6–29) 4.4 (1.2–6.9) 4.9 (1.3–7.7)
15–29 26.6 (13–38) 6.5 (3.3–9.4) 9.9 (5–14.3)
30–44 14 (9–25) 3.6 (1.8–7.1) 5 (2.4–9.9)
45–59 9.1 (4–14) 2.5 (1.1–3.9) 2.7 (1.1–4.2)
60–69 6.6 (3–10) 1.6 (1–2.7) 1.3 (0.8–2.2)
70–79 2.4 (0–4) 0.8 (0–1.5) 0.5 (0–0.9)
80+ 1 (0–3) 0.2 (0–0.8) 0.1 (0–0.4)
Totals 80.6 (45–121) 20.5 (9.2–30) 24.7 (11.4–37.1)BMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
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egory. HAT affects the most productive age groups as illus-
trated by the close association between its age distribution
and the age-productivity function curve of Murray [2] (see
Figure 1). For malaria, the age distribution is skewed with
the majority of cases being less than 5 years of age. The
tuberculosis age distribution is skewed with the majority
of cases occurring among adults.
The proportion of hospital days by disease provides a rea-
sonable estimate of the relative costs to the Serere health
system of different diseases, as the daily hospital costs are
relatively constant across diseases. The proportions of
hospital days for the 6 most common causes of admission
are shown in Figure 2. In 1999, severe malaria accounted
for approximately 40% of hospital days and HAT, 30%.
Discussion
Many countries in sub-Saharan Africa (SSA) are devolving
decision-making for health service delivery to the local
level. Local burden of disease estimates can play an
important role in health sub-districts rationally allocating
resources to the highest priority diseases [22]. The DALY
is currently the most widely accepted measure for estimat-
ing the burden of human disease; in this study, we have
shown that with relatively small-scale datasets available
from a local in-patient health centre, useful estimates of
relative burden can be made. Thus, DALY estimates for
local planning purposes and the relative ranking of
adverse health conditions can be readily estimated from
local health centre data using the data outlined in Table 1.
WHO estimates the treatment costs (hospitalisation and
drugs) per patient of HAT to be in the order of greater than
US $120 [9]; WHO estimates are of the same order as our
estimates of US$147. In addition to the DALY estimates
we present, we show that hospital costs, which are also an
important planning tool for local health decision makers,
can be simply derived from in-patient records, particularly
in countries with good reporting systems [44]. For con-
venience and ease of comparison, we have assumed that
hospitalisation costs are relatively standard across dis-
eases; however, drugs for the treatment of HAT are admin-
istered parentally and, due to toxicity, complications are
frequent, increasing the costs of treatment; our estimates
are thus conservative. In addition, we have not accounted
for costs beyond those to the local health system, such as
costs to individual patients. These may vary by disease,
particularly if appropriate diagnostic facilities are lacking
in rural areas [39].
This is the first study to estimate the DALY specifically for
rhodesiense as opposed to gambiense HAT; local estimates
Table 4: Disability-Adjusted Life Years due to rhodesiense sleeping sickness in Serere, Uganda. Values are mean values (with 95% 
confidence intervals) from 10,000 Monte-Carlo simulations, derived from data from 1999–2005. The DALY score for each age group = 
YLL + YLD for that age group.
DALYs with age weighting DALYs with no age weighting
Age group Assuming 0% under-reporting Assuming 69% under-reporting Assuming 0% under-reporting Assuming 69% under-reporting
0–4 4.3 (0–28.6) 87.3 (17–170.6) 4.4 (0–26.3) 72.2 (13.9–141.6)
5–14 38.2 (4.5–108.1) 428.1 (142.4–909.5) 28.4 (4–80) 313.1 (103.6–666.7)
15–29 29.6 (5–65.5) 562.6 (204.6–1040.8) 21.4 (3.3–48.8) 412.8 (151–761.2)
30–44 15.3 (2.4–27.2) 215.6 (94.1–453.8) 13.4 (1.8–23.4) 188.2 (82.2–398.5)
45–59 4.6 (1.1–16.3) 86 (29.8–158.2) 4.7 (1.1–18) 95.9 (32.5–175.2)
60–69 7.4 (0.8–17.5) 40.7 (11.2–75.9) 10.3 (1–24) 57.2 (16.1–108)
70–79 1.6 (0–5.4) 8.5 (0–20.1) 2.7 (0–9) 14.3 (0–33.9)
80+ 0.3 (0–1.2) 1.7 (0–6.7) 0.6 (0–3.1) 3.7 (0–14.6)
Total 101.2 (39.8–197.1) 1430.5 (623.9–2691.2) 85.9 (35.1–162.1) 1157.3 (504.3–2158.7)
Table 5: Comparison of the mean burden due to sleeping sickness and malaria for Serere health facility, Soroti District, Uganda (data 
for malaria are from 1999 records). The YLLs, YLDs and DALYs figures in parenthesises where calculated with age weighting, while 
those outside the parentheses were calculated without age-weighting.
Sleeping sickness Ratio of sleeping sickness : malaria
No under reporting 69% under-reporting Malaria Observed No under-reporting 69% under-reporting
Cases 84.5 143.5 11,228 1 : 133 1 : 78
In-patients 84.5 84.5 763 1 : 9.0 1 : 9.0
Deaths 4 59 2 1 : 0.50 1 : 0.03
YLLs 65 (76) 1137 (1406) 150.4 (176.6) 1:2.3 (1 : 2.3) 1 : 0.1 (1 : 0.1)
YLDs 21 (25) 21 (25) 120.3 (130.4) 1 : 5.7 (1 : 5.2) 1 : 5.7 (1 : 5.2)
DALYs 86 (101) 1157 (1430) 270.7 (306.9) 1 : 3.1 (1 : 3.0) 1 : 0.23 (1 : 0.21)BMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
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for gambiense HAT are available elsewhere [17]. Given that
HAT of both types is invariably fatal if not treated and that
HAT surveillance is relatively weak throughout sub-Saha-
ran Africa [9], it is not surprising that mortality, particu-
larly mortality due to unreported cases, dominates the
DALY estimate; this is a reflection of the neglected status
of this disease. Given that 95% of treatments for rhode-
siense HAT were successful at Serere health centre, result-
ing in a cost per DALY averted (compared to a "do-
nothing" scenario) of under US$ 10 without accounting
for under-reporting, there are great potential benefits in
enhancing strategies for identifying unreported HAT cases
in the community, and improving reporting rates. As a
general rule, an attractive intervention in developing
countries is one in which the cost per DALY averted is
under US$ 150, and a highly attractive intervention is one
with a cost per DALY of under US$ 25 [45]. Resources tar-
geted at improving reporting and reducing the hidden
burden of HAT would therefore be highly cost-effective.
These results also serve to further emphasise the need for
enhanced surveillance for neglected zoonotic diseases
more generally.
Our estimates of disease burden relate to a period when
the catchment area of the hospital was experiencing an
outbreak of T.b. rhodesiense HAT [21], the disease was pre-
viously absent but has become well-established in this
north-eastern region. While the incidence of reported
HAT appears to have decreased across Africa generally in
the past 5 years [46], Uganda has seen the expansion of
the T.b. rhodesiense-affected zone and the potential for a
much larger number of cases. At regional and local levels,
information about the disease burden over this time
period could be a valuable addition to the decision mak-
ing process for planning public health interventions [24].
Because of its high mortality, relatively acute and severe
clinical course and age distribution, rhodesiense HAT had
a DALY estimate that was high compared to malaria. The
main difficulty in comparing HAT and malaria DALYs is
the problem of estimating the relative rate of under-
reporting of the two diseases based on hospital data.
Though there were 2 reported malaria deaths there are
likely to have been more deaths occurring in the commu-
nity, which were not logged by the health system. The
number of reported cases of malaria (11,228) is 133×
higher than the estimated mean of 85 reported HAT cases
per year; these numbers may not be a good reflection of
the relative incidence of the two diseases, as the standards
for diagnosis differed. For example, many fevers due to
other causes (including early stage HAT) may be diag-
nosed as malaria in hyper-endemic areas resulting in over-
Age distribution of malaria, sleeping sickness and tuberculosis patients admitted to Serere health centre compared to the age-  productivity function curve [2] Figure 1
Age distribution of malaria, sleeping sickness and tuberculosis patients admitted to Serere health centre com-
pared to the age- productivity function curve [2].BMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
Page 9 of 11
(page number not for citation purposes)
reporting. Amexo [41] reported that in Uganda, clinical
diagnosis of malaria without parasitological confirmation
could over-estimate malaria incidence by 43–57%. Con-
versely, many patients, even with severe malaria, will self-
treat and not report to the health units. The magnitude of
mis-reporting and under-reporting for a range of diseases
in Serere deserves further attention. HAT is always con-
firmed through parasitological means, giving us confi-
dence that the HAT incidence, is, at least, not over-
reported. Another complication in comparing the relative
burdens of malaria and HAT is their differing patterns of
occurrence, with malaria having a more widespread inci-
dence than HAT. However, our study does accurately
present the relative burden of the two diseases in that sub-
set of the population that reports for treatment at the
health centre.
Our study did not account for any post-treatment disabil-
ity resulting from HAT infection. This is difficult to quan-
tify; studies in Cameroon [38,47] have shown that
children with a past history of T.b. gambiense HAT had sig-
nificantly lower weight, height and mid-arm circumfer-
ence and spent more years in school. Long term disability
was particularly noted in patients treated for late-stage dis-
ease. No similar studies exist for T.b. rhodesiense.
Recent economic impact assessments of trypanosomiasis
control in livestock have excluded the public health bur-
den of the disease [10,11,48]. Our T. b. rhodesiense HAT
DALY estimates in eastern Uganda indicate that where T.
b. rhodesiense HAT outbreaks occur, the disease has an
important impact on human health. This public health
impact needs to be considered in overall tsetse and
trypanosomiasis control planning. Trypanosomiasis in
cattle is an important veterinary problem in much of
Uganda and East Africa, and both tsetse control and treat-
ment of cattle fall under the mandate of the Ministries of
Agriculture of most governments in Africa. The treatment
of livestock for trypanosomiasis is one of the important
control strategies where T. b. rhodesiense HAT occurs
because cattle are the main reservoir of zoonotic human-
infective trypanosomes [12-14]. This study highlights
some preliminary analyses [49] that have shown that
coordinated control of animal and human trypanosomi-
ases would be economically beneficial, with benefits to
both the livestock and public health sectors by reducing
the burden on health services; further work is required to
estimate the DALY reduction from a given effort in con-
trolling trypanosomiasis in the animal reservoir.
Our DALY estimate for rhodesiense HAT in Serere,
Uganda, has shown that mortality due to unreported cases
was the major contributor to its burden on the local pop-
ulation, while reported cases of T.b. rhodesiense HAT alone
consumed 30% of in-patient time in Serere health centre;
the disease has now become well established in the region
[21], and continues to spread to areas where under-report-
ing is likely to be accentuated [50]. The parameters used
in our model could be usefully applied to other settings in
East Africa. Thirteen countries are considered to be
endemic for T.b. rhodesiense [46], with varying incidence
and under-reporting rates; efforts need to be mustered to
make best use of what data are available in treatment cen-
tres and hospitals in each HAT focus, to estimate the level
of under-reporting in a manner appropriate to each focus,
and to use this to estimate DALYs lost due to the disease.
Percent of hospital days for inpatients by condition at Serere health centre in 1999 Figure 2
Percent of hospital days for inpatients by condition at Serere health centre in 1999.BMC Public Health 2008, 8:96 http://www.biomedcentral.com/1471-2458/8/96
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Finally, our analysis employs a stochastic framework to
estimate both the disease and economic burden of HAT in
this community. Early disease burden assessments were
deterministic in nature [3,16], where uncertainty in the
diverse inputs for the calculations is not reflected in the
outputs. This has been the case even for large-scale
national and regional studies [26,51], although there are
increasing numbers of studies on neglected diseases that
do quantify uncertainty [8,52-54]. Quantifying uncer-
tainty explicitly increases the value of DALY outputs as a
tool in decision making, and, importantly, helps to iden-
tify gaps in knowledge for some parameters.
Conclusion
The relative burden of HAT can be usefully assessed using
a variety of methods, especially the DALY, at regional and
sub-regional levels using data from local hospital records
and reporting systems. This is particularly important for
focal diseases which may greatly affect one community
and be absent from another. The disability weighting used
in previous DALY assessments of HAT did not appropri-
ately account for the different YLDs for early and late stage
disease; in addition, as we have emphasised here, T.b.
rhodesiense  and  T.b. gambiense should be separately
accounted for in wider scale burden assessments in future
because they present as such clinically distinct diseases. In
our study site centred on one treatment centre, T.b. rhode-
siense HAT resulted in a mean of 1157 DALYs lost per year
(without age-weighting), with unreported cases represent-
ing the greatest majority of this burden.
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